Viatris Stock News

The company in a statement said that its subsidiary Biocon Biologics has inked a pact to acquire Viatris Inc''s biosimilars business for consideration of up to USD 3.335 billion

Premium valuation of the deal, the taking on of high debt and potential for margin dilution are key reasons for the fall

When Biocon said it will buy US-based Viatris Inc''s biosimilars business in a transaction valued at $3.34 billion that will increase debt on its books, the market did not take it kindly.

Viatris (VTRS) misses on Q4 earnings but surpasses sales estimates. The company announces a combination of its biosimilars portfolio with Biocon Biologics.

Viatris (NASDAQ: VTRS) announced its Q4 results and sale of its biosimilar assets to India''s Biocon Biologics for up to $3.335B.Viatris Q4 total revenue rose 19.82% Y/Y to $4.34B.Net…

Viatris reported solid fiscal 2021 earnings, after having increased guidance on multiple occasions.

Biocon Biologics Ltd has agreed to acquire Viatris Inc's (NASDAQ: VTRS) biosimilars assets for up to $3.335 billion in stock and cash. The deal value includes cash of up to $2.335 billion and Comp

Viatris (VTRS) delivered earnings and revenue surprises of -2.44% and 0.71%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

(Reuters) -Viatris Inc, the drugmaker formerly known as Mylan, said on Monday it had agreed to pay $264 million to resolve a class action lawsuit alleging it engaged in a scheme to delay generic compe

Viatris Inc. VTRS, +4.38% , the company formed by the merger of Mylan and Pfizer Inc. PFE, +3.83% unit Upjohn in 2020, said Monday it has reached an agreement to combine its biosimilars portfolio with

BBL will also obtain Viatris'' rights in all biosimilars assets, including its in-licensed portfolio and an option to acquire Viatris'' rights in bAflibercept

Viatris (NASDAQ:VTRS) is scheduled to announce Q4 earnings results on Friday, February 25th, after market close.The consensus EPS Estimate is $0.75 and the consensus Revenue Estimate…

In recent trading session, Viatris Inc. (NASDAQ:VTRS) saw 3.26 million shares changing hands at last check today with its beta currently measuring 1.30. Company’s recent per share price level of $14.38 trading at $0.45 or 3.23% at last check today assigns it a market valuation of $16.98B. That most recent trading price of VTRS’s stock … Viatris Inc. (NASDAQ:VTRS) Currently -13.28% Below Its 52-Week High But The Downside Potential May Surprise You Read More »

Viatris (VTRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.